<DOC>
	<DOC>NCT02173912</DOC>
	<brief_summary>This study is designed to evaluate the bioequivalence of the two treatments, the administration of CJ-30059 and the co-administration of candesartan cilexetil and amlodipine besylate, in healthy volunteers.</brief_summary>
	<brief_title>Bioequivalence Study of CJ-30059</brief_title>
	<detailed_description />
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Male volunteers in the age between 19 and 55 years old(inclusive) Body mass index (BMI) in the range of 18.5 to 27 kg/m2(inclusive) Available for the entire study period Understand the requirements of the study and voluntarily consent to participate in the study Subjects with a history of gastrointestinal diseases which might significantly change absorption, distribution, metabolism and excretion (ADME) of medicines Systolic blood pressure outside the range of 100 to 150 mmHg or diastolic blood pressure outside the range of 70 to 1000 mmHg for male subjects during screening Subject with symptoms of acute disease within 14days prior to study drug administration Subjects with a history of clinically significant allergies Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase deficiency or glucosegalactose malabsorption Subjects whose clinical laboratory test values are outside the accepted normal range. Especially, aspartate aminotransferase (AST) or alamin aminotransferase (ALT) &gt;1.5 times of the Upper Normal Limit or total bilirubin &gt; 1.5 times of the Upper Normal Limit) History of drug abuse History of caffeine, alcohol, smoking abuse caffeine(coffee, tea, coke) or grapefruit juice &gt; 4 cups/day smoking &gt; 20 cigarettes/day alcohol &gt; 140 g/week Positive test results for Hepatitis B antibodies, Hepatitis C virus antibody, and Syphilis regain test Participation in any clinical investigation within 30 days prior to study drug administration Subjects with whole blood donation within 60 days, component blood donation within 30days and blood transfusion within 30 days prior to study drug administration Subjects who are judged unsuitable by investigators</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>